Anales de la RANM

32 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LA MEDICINA DE PRECISIÓN Y EL PACIENTE ALÉRGICO Tomás Chivato Pérez Año 2018 · número 135 (01) · páginas 28 a 32 présentant plusieurs allergies alimentaires sévères. Revue francaise d´allergologie 2010 (50) : 513-515. 11. Sub-lingual Immunotherapy : World Allergy Orga- nization Position Paper 2009. Allergy 2009;64(Sup- pl 91): 1-59. 12. Chivato T, Álvarez-Calderón P, Panizo C, et al. Cli- nical management, expectations, and satisfaction of patients with moderate to severe allergic rhinocon- junctivitis treated with SQ-standardized grass-aller- gen tablet under routine clinical practice conditions in Spain. Clin Mol Allergy. 2017 6;15:18. 13. Holgate ST, Casale T, Wenzel S, Bousquet J. The an- tiinflammatory effects of omalizumab confirm the central role of IgE in allergic inflamation. J Allergy Clin Immunol 2005 ;35 :408-416. 14. Ancochea J, Chivato T, Casan P, Picado C, Herráez L, Casafont J.Profile of patients treated with omali- zumab in routine clinical practice in Spain. Aller- gol Immunopathol (Madr). 2014;42(2):102-108. 15. Alergológica 1992. Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades Alérgicas en España. Ed. SEAIC & ALK-Abelló. 1992. 1-325. 16. Alergológica 2005. Factores epidemiológicos, clíni- cos y socioeconómicos de las enfermedades Alér- gicas en España. Ed. SEAIC & Schering-Plough. 2005. 1-386. 17. Alergológica 2015. Factores epidemiológicos, clíni- cos y socioeconómicos de las enfermedades Alérgi- cas en España. Ed. SEAIC &FAES. 2017. 1-352. 18. T Chivato. Allergy: Living&Learning: la percep- ción del paciente alérgico. Alergol e Inmunol Clin 2002; 17 (extr 2):116-122. 19. Dahl R, Andersen PS, Chivato T, Valovirta E, De Monchy J. National prevalence of respiratory al- lergic disorders. Respir Med 2004; 98(5):398-403. 20. De Monchy J, Andersen PS, Bergmann KC, et al. Living&learning with allergy: a European percep- tion study on respiratory allergic disorders. Respir Med 2004; 98(5):404-412. 21. Chivato T, Valovirta E, Dahl R, et al. Living and Learning: Diagnosis and Treatment of Allergic Re- spiratory Diseases in Europe. J Investig Allergol Clin Immunol 2012; 22(3): 168-179. 22. Molecular Allergology User´s Guide. Published by the European Academy of Allergy and Clinical Im- munology 2016. www.eaaci.org. 1-401. 23. Bandrés, F. Marañón: De la Medicina Clínica a la Medicina Personalizada. Conferencia 5 abril 2017. Real Academia Nacional de Medicina. 24. Villaseñor A, Rosace D, Obeso D, et al. Allergic asthma: an overview of metabolomic strategies leading to the identification of biomarkers in the field. Clin Exp Allergy. 2017;47(4):442-456. 25. Barber D1, Díaz-Perales A, Villalba M, Chivato T. Challenges for allergy diagnosis in regions with complex pollen exposures. Curr Allergy Asthma Rep. 2015;15(2):496-498 26. Bousquet J, Hellings PW, Agache I et al. ARIA 2016: Care pathways implementing emerging tech- nologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016; 30;6:47. 27. Bousquet J1, Bewick M, Cano A, Eklund P, Fico G, Goswami N. Building Bridges for Innovation in Age- ing: Synergies between Action Groups of the EIP on AHA. J Nutr Health Aging. 2017;21(1):92-104. Si desea citar nuestro artículo: Chivato-Pérez T. La medicina de precisión y el paciente alérgico. ANALES RANM [Internet]. Real Academia Nacional de Medicina de España; 2018 Sep 3;135(01):28–32. DOI: http://dx.doi.org/10.32440/ar.2018.135.01.rev04